Modulation of Bax and mTOR for cancer therapeutics

A rationale exists for pharmacologic manipulation of the serine (S)184 phosphorylation site of the proapoptotic Bcl2 family member Bax as an anticancer strategy. Here we report the refinement of the Bax agonist SMBA1 to generate CYD-2-11, which has characteristics of a suitable clinical lead compoun...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Cancer Res
Main Authors: Li, Rui, Ding, Chunyong, Zhang, Jun, Xie, Maohua, Park, Dongkyoo, Ding, Ye, Chen, Guo, Zhang, Guojing, Gilbert-Ross, Melissa, Zhou, Wei, Marcus, Adam I., Sun, Shi-Yong, Chen, Zhuo G., Sica, Gabriel L., Ramalingam, Suresh S., Magis, Andrew T., Fu, Haian, Khuri, Fadlo R., Curran, Walter J., Owonikoko, Taofeek K., Shin, Dong M., Zhou, Jia, Deng, Xingming
Formato: Artigo
Idioma:Inglês
Publicado: 2017
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5503158/
https://ncbi.nlm.nih.gov/pubmed/28381544
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-16-2356
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares